ArticleResearch and practice in thrombosis and haemostasis2024

Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.

Guy Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.